|
Synonyms: Tarvacin ch3G4
Compound class:
Antibody
Comment: Bavituximab is the first monoclonal antibody directed against phosphatidylserine, and is being investigated as a antineoplastic agent. Bavituximab belongs to an emerging class of antibodies known as vascular targeting agents (VTAs) which bind selectively to antigens present on tumour vascular cells. Typical VTAs either recruit host effector cells to destroy the tumour or are coupled to agents such as toxins, anticoagulants or pro-apoptotic drugs that occlude or destroy tumour blood vessels [3].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| References |
|
1. DeRose P, Thorpe PE, Gerber DE. (2011)
Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy, 3 (8): 933-44. [PMID:21843081] |
|
2. Ran S, Downes A, Thorpe PE. (2002)
Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res, 62 (21): 6132-40. [PMID:12414638] |
|
3. Thorpe PE. (2004)
Vascular targeting agents as cancer therapeutics. Clin Cancer Res, 10 (2): 415-27. [PMID:14760060] |
|
4. Thorpe PE. (2010)
Targeting anionic phospholipids on tumor blood vessels and tumor cells. Thromb Res, 125 Suppl 2: S134-7. [PMID:20433993] |
|
5. Yin Y, Huang X, Lynn KD, Thorpe PE. (2013)
Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol Res, 1 (4): 256-68. [PMID:24777853] |
